San Antonio Breast Cancer Symposium 2019: human epidermal growth factor receptor  2(HER2)-positive breast cancer and image-guided biopsy to detect pathologic complete response (pCR)

SummaryAt the 2019 San Antonio Breast Cancer Symposium, new data on the management of heavily pretreated human epidermal growth factor receptor 2(HER2)-positive metastatic breast cancer were discussed. The phase  3 HER2CLIMB and the phase 2 DESTINY-Breast01 trials investigating tucatinib and trastuzumab deruxtecan, respectively, have met their primary endpoints.In an early disease setting, four studies investigated whether image-guided biopsies could identify patients with a  pathologic complete response (pCR) to neoadjuvant chemotherapy, thus allowing safe omission of surgery. As residual disease was missed in a significant number of cases, these trials could not confirm data from smaller previous studies.
Source: Memo - Magazine of European Medical Oncology - Category: Cancer & Oncology Source Type: research